Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Renalytix plc - Sponsored ADR RNLXY

Healthcare  —  Health Information Services
4.00 (0.17) (4.08%) as of 24 Sep
Market cap
$17.2M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Renalytix AI PLC Sponsored ADR (RNLXY) Business Profile

Updated before January 2025

Company Overview

Renalytix AI PLC Sponsored ADR (RNLXY) is a pioneering healthcare technology company specializing in the development of artificial intelligence (AI)-driven solutions for kidney disease diagnosis and management. Founded in 2018, the company is headquartered in London, United Kingdom, with operations extending to the United States and other global markets. Renalytix was established with the mission of transforming kidney health management through advanced diagnostics and predictive analytics. The company is led by a team of seasoned professionals, including CEO James McCullough, who brings extensive experience in healthcare innovation and commercialization. Other key leadership figures include Fergus Fleming, the Chief Technology Officer, and Thomas McLain, the President, who collectively drive the company’s strategic vision and operational excellence.

Core Business Segments

Renalytix operates primarily in the healthcare diagnostics sector, focusing on the following core business segments:

1. KidneyIntelX™

The flagship product of Renalytix, KidneyIntelX™, is an AI-enabled diagnostic platform designed to improve early detection and risk stratification of chronic kidney disease (CKD). By integrating electronic health records (EHR) data, blood-based biomarkers, and machine learning algorithms, KidneyIntelX™ provides actionable insights to healthcare providers. This enables personalized treatment plans and better patient outcomes.

2. Data Analytics and Predictive Modeling

Renalytix also offers advanced data analytics and predictive modeling services. These services are aimed at healthcare systems and providers, helping them optimize resource allocation, reduce costs, and improve patient care. The company’s AI-driven models are tailored to predict disease progression and identify high-risk patients.

3. Collaborative Research and Development

Renalytix collaborates with leading academic institutions, healthcare providers, and pharmaceutical companies to develop innovative diagnostic tools and therapies. These partnerships are instrumental in expanding the company’s product portfolio and enhancing its technological capabilities.

Business Model

Renalytix’s business model is centered around leveraging AI and machine learning to deliver value-driven healthcare solutions. The company generates revenue through:

  • Product Sales: KidneyIntelX™ is sold to healthcare providers and systems, generating recurring revenue streams.
  • Licensing Agreements: Renalytix licenses its proprietary technology to partners, enabling them to integrate AI-driven diagnostics into their workflows.
  • Collaborative Projects: The company earns revenue through joint research and development initiatives with pharmaceutical companies and academic institutions.
  • Service Contracts: Renalytix provides data analytics and consulting services to healthcare organizations, further diversifying its income streams.

Strategic Direction

Renalytix is committed to expanding its footprint in the global healthcare market. Key strategic initiatives include:

  • Scaling KidneyIntelX™ Adoption: The company aims to increase the adoption of KidneyIntelX™ across major healthcare systems in the United States and Europe.
  • Expanding Product Portfolio: Renalytix is actively investing in research and development to introduce new diagnostic tools for other chronic diseases.
  • Sustainability Goals: The company is focused on reducing healthcare costs and improving patient outcomes, aligning with broader sustainability objectives in the healthcare sector.
  • Global Partnerships: Renalytix plans to strengthen its collaborations with international healthcare providers and pharmaceutical companies to drive innovation and market penetration.

Competitive Landscape

Renalytix operates in a competitive market, facing challenges from both established players and emerging startups. Key competitors include:

  • BioMérieux: A global leader in in-vitro diagnostics, offering a wide range of diagnostic solutions.
  • Roche Diagnostics: Known for its advanced diagnostic tools and strong market presence.
  • Veracyte: A company specializing in genomic diagnostics for various diseases, including kidney-related conditions.
  • Health Catalyst: A data analytics company providing solutions for healthcare systems, overlapping with Renalytix’s analytics offerings.

Despite the competition, Renalytix differentiates itself through its focus on AI-driven diagnostics and its flagship product, KidneyIntelX™.

Risk Factors

Renalytix faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The company’s products must comply with stringent regulatory requirements, which can delay market entry.
  • Market Dependence: A significant portion of revenue is tied to the success of KidneyIntelX™, making the company vulnerable to market fluctuations.
  • Supply Chain Disruptions: Dependence on third-party suppliers for raw materials and components poses a risk of supply chain interruptions.
  • Technological Competition: Rapid advancements in AI and diagnostics could render Renalytix’s technology obsolete if the company fails to innovate.

Recent Developments

Renalytix has made significant strides in recent years, including:

  • FDA Clearance for KidneyIntelX™: The company received FDA clearance for its flagship product, paving the way for broader adoption in the U.S. market.
  • Partnership with Mount Sinai Health System: Renalytix has partnered with Mount Sinai to implement KidneyIntelX™ across its network, demonstrating the product’s clinical utility.
  • Expansion into European Markets: The company has initiated efforts to introduce its products in Europe, targeting countries with high CKD prevalence.
  • Technological Innovations: Renalytix continues to enhance its AI algorithms, improving the accuracy and reliability of its diagnostic tools.

Investment Considerations

Investors considering Renalytix should weigh the following factors:

Strengths

  • Innovative Technology: Renalytix’s AI-driven approach sets it apart in the diagnostics market.
  • Strong Partnerships: Collaborations with leading healthcare providers and academic institutions bolster the company’s credibility.
  • Market Potential: The growing prevalence of CKD presents a significant market opportunity for KidneyIntelX™.

Risks

  • Regulatory Hurdles: Delays in regulatory approvals could impact product launches and revenue growth.
  • Financial Performance: As a relatively young company, Renalytix may face challenges in achieving consistent profitability.
  • Competitive Pressure: The presence of established players in the diagnostics market poses a threat to market share.

Conclusion

Renalytix AI PLC Sponsored ADR (RNLXY) is at the forefront of transforming kidney disease management through AI-driven diagnostics. With its innovative products, strategic partnerships, and commitment to improving patient outcomes, the company is well-positioned for growth. However, investors should remain mindful of the risks associated with regulatory challenges and market competition. Overall, Renalytix represents a compelling opportunity in the healthcare technology sector, with significant potential for long-term value creation.